Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012Ranee Mehra, Robert I. Haddad, Hyun Cheol Chung et al.|British Journal of Cancer|2018Cited by 457
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III studyRobert L. Ferris, Lisa Licitra, Robert I. Haddad et al.|Annals of Oncology|2020Cited by 365
Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC).Robert I. Haddad, Ranee Mehra, Tanguy Y. Seiwert et al.|Journal of Clinical Oncology|2017Cited by 56
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012.Ranee Mehra, Robert I. Haddad, Tanguy Y. Seiwert et al.|Journal of Clinical Oncology|2016Cited by 45
EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).Lisa Licitra, Robert L. Ferris, Robert I. Haddad et al.|Journal of Clinical Oncology|2019Cited by 39